Rheumatoid arthritis definition

Feldmann M (1996). The cytokine network in rheumatoid arthritis definition of TNF alpha as a therapeutic target. J. Royal Coll. Physicians of London. 30 560-570. 

The definition of an overlap syndrome dictates that the criteria for diagnosis of both disorders (in the present context, of PM/DM and of some other connective tissue disorder), are fulfilled. It is not unexpected that those syndromes which overlap with PM/DM are also either known autoimmune conditions or ones in which an autoimmune basis is strongly suspected. The association of these disorders with PM/DM syndromes may not materially alter the basic histopathological featmes expected in PM/DM but some differences may be identifiable. The disorders most frequently associated with an overlap syndrome are rheumatoid arthritis, systemic lupus erythematosis, scleroderma, and mixed connective tissue disease. 

For classification purposes, a patient is said to have rheumatoid arthritis if he or she has satisfied at least four of these seven criteria. Criteria 1 through 4 must be present for at least 6 weeks. Patients with two clinical diagnoses are not excluded Designation as classic definite, or probable rheumatoid arthritis is not to be made. 

Rheumatoid arthritis Indicated only in adult patients meeting criteria for classic or definite rheumatoid arthritis as specified by the American Rheumatism Association. Restrict use to patients with severe, active, and erosive disease not responsive to conventional management. 

Azathioprine and mercaptopurine appear to be of definite benefit in maintaining renal allografts and may be of value in transplantation of other tissues. These antimetabolites have been used with some success in the management of acute glomerulonephritis and in the renal component of systemic lupus erythematosus. They have also proved useful in some cases of rheumatoid arthritis, Crohn s disease, and multiple sclerosis. The drugs have been of occasional use in prednisone-resistant antibody-mediated idiopathic thrombocytopenic purpura and autoimmune hemolytic anemias. 

J9. Jones, V., Jacoby, R., Wallington, T., and Holt, P., Immune complexes in early arthritis Detection of immune complexes before rheumatoid arthritis is definite. Clin. Exp. Immunol. 44, 512-521 (1981). 

Methotrexate is used widely as a DMARD for rheumatoid arthritis, psoriatic arthritis, and for its steroid-sparing effects in many other conditions, especially if azathioprine is not tolerated. In high dose, with folinic acid rescue, methotrexate is used to treat solid and haematological malignancies (see p. 612). Low dose methotrexate slows the progression of rheumatoid arthritis. The evidence for a true disease-modifying effect on psoriatic arthritis is less definite, but methotrexate is often preferred to other DMARDs for its beneficial effect on the skin lesions. 

In patients with definite or probable methotrexate-induced lung injury, the predominant clinical features include shortness of breath, cough, and fever (13). Pathological examination usually shows an interstitial inflammatory cell infiltrate (sometimes granulomatous or with alveolar damage), and variable degrees of interstitial fibrosis. Unfortunately, confirmatory evidence is sometimes hard to obtain, particularly in patients with rheumatoid arthritis in whom rheumatoid interstitial lung disease can also occur. Infectious pneumonias, particularly viral or Pneumocystis jiroveci pneumonia, which resemble methotrexate pneumonitis and can occur as a result of immunosuppression, should also be carefully excluded. 

The prevalence of methotrexate pneumonitis has been variably estimated from 0.3 to 18%, with a mean estimated prevalence of 3.3% (14,16). In a review of the respiratory complications of methotrexate, the authors concluded that pneumonitis occurs in 7% of patients, in 25% of whom it is fatal as a result of respiratory failure (18). This can occur with any dose of methotrexate, given via any route it has occurred after the intrathecal administration of 12 mg given for central nervous system prophylaxis (19). In a review of 194 patients with rheumatoid arthritis and 38 with psoriatic arthritis, the prevalences of pneumonitis were 2.1 and 0.03% respectively (14), which is similar to the 3.2% incidence in a prospective study of 124 patients with rheumatoid arthritis (20). Another analysis performed over 5 years showed that the estimated prevalence of definite or probable pneumonitis was only 0.86% in 1162 patients (10 patients, of whom three died), but this conclusion was based on a limited retrospective identification of cases (21). 

Because antibodies bind to antigens, their function is often to augment intrinsic clearance mechanisms as well as potentially exerting definitive therapeutic effects. It is not surprising, therefore, that the therapeutic targets for antibody therapy are extremely broad, ranging from antitumor therapy to specific immunological diseases, for example rheumatoid arthritis. 

Studies of autoantibodies in the general population allow us to determine the prevalence of specific autoantibodies among people who do not have a clinically evident autoimmune disease, whether the prevalence of autoantibodies reflects the demographic variation in disease risk and whether specific environmental exposures are related to the expression of specific autoantibodies. These studies are most feasible for the autoantibodies associated with the most common autoimmune diseases diabetes mellitus type 1, autoimmune thyroid disease, and rheumatoid arthritis. Important issues with respect to interpreting these types of studies include the type of test used and definition of a positive result. 

Nested case-control M (157, 157) Gold miners Silicosis and definite or probable rheumatoid arthritis OR 2.8 (P < 0.01) higher association seen with definite disease and with rheumatoid factor Sluis-Cremer et al. (1986)... 

See footnotes in Table 6.5 for the definition of clinical result classifications for acute rheumatic fever, rheumatoid arthritis, and cervical spine-shoulder and lumbar spine syndromes. 

Oral antimicrobial agents sometimes have beneficial effects in inflammatory bowel disease. However, in the absence of any evidence pointing toward a definite microbial cause for the colitis in this patient, a drug that decreases inflammation is indicated. Sulfasalazine has significant anti-inflammatory action, and its oral use results in symptomatic improvement in 50-75% of patients. The drug is also used for its anti-inflammatory effects in rheumatoid arthritis. The answer is (D). 

Patients with osteoarthritis or rheumatoid arthritis are randomized to one of three treatments, celecoxib, ibuprofen, or naproxen, and the primary endpoint is the occurrence of a cardiovascular endpoint a nonfatal myocardial infarction, a nonfatal stroke, or any cardiovascular death. Non-inferiority will be assessed for three different pairwise comparisons celecoxib versus ibuprofen, celecoxib versus naproxen, and ibuprofen versus naproxen. The definition of non-inferiority differs somewhat from the fixed margin approach describe earlier in that there are separate criteria for the confidence interval and the point estimate. The hazard ratio for each comparison will be calculated, and non-inferiority will be concluded if the upper end of the... 

---